Empagliflozin ‘cuts HF risk’ regardless of natriuretic peptide levels
Furthermore, levels of the biomarker after 12 weeks of therapy are prognostic, researchers report
Empagliflozin reduces the risk of adverse cardiovascular and renal outcomes in people with heart failure regardless of their baseline N-terminal pro–B-type natriuretic peptide levels, researchers report.
In a further analysis of data from the EMPEROR-Reduced trial, the US-led researchers sought to assess the relationship between these benefits and N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentrations at baseline and during the trial.
In the trial, patients with heart failure with reduced ejection fraction (HFrEF) were randomly assigned to placebo or empagliflozin 10mg daily.
NT-proBNP was measured at baseline, four weeks, 12 weeks, 52 weeks, and 100 weeks.
